ATG9B and glioma: To track the therapeutic potential of the ASCL2‐ATG9B axis in more detail, we identified ROC‐325, an autophagy inhibitor with high BBB permeability and effectivity, as a single agent for the treatment of ASCL2‐ATG9B AxisHigh glioma cells.